Malignant neoplasm of prostate
|
0.370 |
Biomarker
|
disease |
BEFREE |
Taken together, this study demonstrates a potential role for IL-27 in the treatment of prostate cancer.
|
31009295 |
2019 |
Malignant neoplasm of prostate
|
0.370 |
Biomarker
|
disease |
BEFREE |
IL-30 silencing in PC-SLCs prevented lung metastasis in 73% of tumor-bearing WT mice and up to 80% in tumor-bearing IL-30KO mice.
|
31366386 |
2019 |
Malignant neoplasm of prostate
|
0.370 |
Biomarker
|
disease |
BEFREE |
Here, we asked whether IL30 may favor prostate cancer progression by conditioning PCSLCs and assessed the value of blocking IL30 to suppress tumor growth.
|
29487200 |
2018 |
Malignant neoplasm of prostate
|
0.370 |
Biomarker
|
disease |
BEFREE |
We, thus, investigated whether IL-27 may function as anti-tumor agent in human (h) PCa and analyzed the rationale for its clinical application.
|
24681516 |
2014 |
Malignant neoplasm of prostate
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
We applied the IL-27 gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of prostate cancer at a bone metastatic site in vivo.
|
24028178 |
2013 |
Malignant neoplasm of prostate
|
0.370 |
Biomarker
|
disease |
BEFREE |
We have explored the potential of a novel cytokine, interleukin-27 (IL-27), for inhibiting this malignant crosstalk, and have examined the effect of autocrine IL-27 on prostate cancer cell gene expression, as well as the effect of paracrine IL-27 on gene expression in bone and T cells.
|
23086758 |
2013 |
Malignant neoplasm of prostate
|
0.370 |
Therapeutic
|
disease |
CTD_human |
We applied the IL-27 gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of prostate cancer at a bone metastatic site in vivo.
|
24028178 |
2013 |
Malignant neoplasm of prostate
|
0.370 |
Biomarker
|
disease |
BEFREE |
We also examined the potential of IL-27 gene delivery by sonoporation to treat and reduce the growth of prostate cancer in vivo.
|
21801027 |
2011 |
Malignant neoplasm of prostate
|
0.370 |
Therapeutic
|
disease |
CTD_human |
We also examined the potential of IL-27 gene delivery by sonoporation to treat and reduce the growth of prostate cancer in vivo.
|
21801027 |
2011 |
Diabetes Mellitus, Insulin-Dependent
|
0.340 |
Biomarker
|
disease |
BEFREE |
Our study reveals that IL-27 contributes to autoimmunity in NOD mice through multiple mechanisms and provides substantial evidence to support its pathogenic role in human T1D.
|
31801074 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Most remarkably, we identify a common missense variant in IL27, associated with type 1 diabetes that results in decreased functional activity of the protein and reduced expression levels of downstream IRF1 and STAT1 in CD4+ T cells only.
|
28248954 |
2017 |
Diabetes Mellitus, Insulin-Dependent
|
0.340 |
Biomarker
|
disease |
BEFREE |
IL-27 blockage delays the onset of diabetes in non obese diabetes mouse, but its role in type 1 diabetes (T1D) in human has not been reported yet.
|
23294976 |
2013 |
Diabetes Mellitus, Insulin-Dependent
|
0.340 |
Biomarker
|
disease |
BEFREE |
The microarray data provided evidence that viral infection, and IL-27 and IL-9 cytokine signalling contributed to the onset of T1D in two of the quadruplets.
|
22108602 |
2012 |
Diabetes Mellitus, Insulin-Dependent
|
0.340 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.
|
19430480 |
2009 |
Prostatic Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases.
|
24028178 |
2013 |
Prostatic Neoplasms
|
0.330 |
Therapeutic
|
group |
CTD_human |
These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases.
|
24028178 |
2013 |
Prostatic Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
Overall, our results suggest that IL-27 may be able to modify interactions between prostate tumor and bone microenvironment cells and thus could be used as a multifunctional therapeutic for restoring bone homeostasis while treating metastatic prostate tumors.
|
23086758 |
2013 |
Prostatic Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
Our results suggest that IL-27 can be effective in reducing tumor growth and can help enhance accumulation of effector cells in prostate tumors in vivo.
|
21801027 |
2011 |
Prostatic Neoplasms
|
0.330 |
Therapeutic
|
group |
CTD_human |
Our results suggest that IL-27 can be effective in reducing tumor growth and can help enhance accumulation of effector cells in prostate tumors in vivo.
|
21801027 |
2011 |
Diabetes, Autoimmune
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.
|
19430480 |
2009 |
Brittle diabetes
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.
|
19430480 |
2009 |
Diabetes Mellitus, Ketosis-Prone
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.
|
19430480 |
2009 |
Diabetes Mellitus, Sudden-Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.
|
19430480 |
2009 |
Crohn Disease
|
0.170 |
GeneticVariation
|
disease |
GWASCAT |
A Genome-wide Association Study Identifying RAP1A as a Novel Susceptibility Gene for Crohn's Disease in Japanese Individuals.
|
30500874 |
2019 |
Ulcerative Colitis
|
0.170 |
AlteredExpression
|
disease |
BEFREE |
In both CD and UC, interleukin (IL)-12 (p40), IL-18, IL-21 and IL-27 transcript levels were higher than in Control.
|
28533995 |
2017 |